Eisai Co., Ltd. (4523)

6,159.0 -39.0 (-0.63%)
Closed JPY Disclaimer

Eisai Co., Ltd. Company Profile

Equity Type
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Contact Information
Tokyo,112-8088 Japan
81 3 3817 3700
Top Executives
Yuko Yasuda 62 2023 Outside Independent Director
Yoshiteru Kato 63 2017 Director
Ryota Miura 49 2021 Independent Outside Director
Richard Thornley 59 2022 Outside Independent Director
Hideyo Uchiyama 70 2018 Independent Outside Director
Yumiko Miwa 58 2020 Independent Outside Director
Toru Moriyama 69 2023 Outside Independent Director
Fumihiko Ike 71 2021 Independent Outside Chairman
Hideki Hayashi 66 2019 Director
Hiroyuki Kato 66 2022 Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.